Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery | Clinical Trial - BRIDGE


The goal of the trial was to compare a strategy of anticoagulation interruption compared with low molecular weight heparin bridge therapy among patients with atrial fibrillation undergoing an invasive procedure.

Contribution to the Literature: The BRIDGE trial showed that low molecular weight heparin bridging did not prevent perioperative arterial thromboembolism, but did increase major bleeding.